TECregen is a Swiss biotechnology company focused on regenerative immunology, engineering thymopoietics to regenerate the thymus and restore immune balance. The company develops first-in-class therapies aimed at immune decline, cancer, and inflammatory diseases, with research and development activities centered in Switzerland. TECregen integrates advanced ligand engineering, targeted delivery, and functional screening to drive thymus regeneration and long-lasting immune restoration. The organization positions itself as a leader in a new class of regenerative biologics.